Pamidria Injection 30 mg 1 Vial

 2,375.00

Manufactured by:
Active Pharmaceutical Ingredient:
Drug Strength: 30 mg
Drug Form : Injection
Pack Size : 1 vial
Does this requires a prescription ?Yes

Pamidria Injection contains Pamidronate Disodium | belongs to Diphosphonate

SKU: pg_17692_24487 Category:

Alternate brands

  • Pamidria Injection 60 mg 1 Vial
     3,960.00
  • You will pay -1585 more
  • Pamidria Injection 90 mg 1 Vial
     6,330.00
  • You will pay -3955 more
  • Osteopam Injection 90 mg 1 Vial
     6,330.00
  • You will pay -3955 more
  • Osteopam Injection 30 mg 1 Vial
     2,375.00
  • You can save 0
  • Medac Disodium Pamidronate Injection 30 mg 1 Vial
     2,375.00
  • You can save 0

    Reviews

    There are no reviews yet.

    Be the first to review “Pamidria Injection 30 mg 1 Vial”

    How it works

    Pamidria Injection 30 mg 1 Vial works by slowing bone breakdown, increasing bone density (thickness) and decreasing the amount of calcium released from the bones into the blood.

    Side effects

    Major & minor side effects for Pamidria Injection 30 mg 1 Vial

    • Black or Tarry stools
    • Blurred vision
    • Chest pain
    • Confusion
    • Dizziness and Drowsiness
    • Fainting
    • Loss of appetite
    • Cough
    • Extreme fatigue
    • Irregular breathing
    • Difficult or painful urination
    • Difficulty in swallowing rare
    • Itching rare
    • Redness of the eye rare
    • Nervousness rare

    Uses of Pamidria Injection 30 mg 1 Vial

    What is it prescribed for?

    • Hypercalcemia of malignancy

      This medicine is used in the treatment of elevated levels of calcium in the blood caused by certain type of cancers.

    • Paget's disease

      This medicine can be used to treat Paget's disease of bone, a condition in which the bones are weak, thin, deformed, and easily fractured.

    • Osteolytic bone metastases of breast cancer

      This medicine is used to treat bone fractures or bone damage in patients with breast cancer.

    • Osteolytic bone lesions of multiple myeloma

      This medicine is used to prevent bone fractures and to treat bone pain caused by osteolytic bone lesions in multiple myeloma patients.

    Concerns

    Frequently asked questions

    • Onset of action

      The amount of time required for this medicine to show its action is not clinically established.

    • Duration of Effect

      The amount of time for which this medicine remains active in the body is not clinically established.

    • Safe with Alchohol?

      Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

    • Is it habit forming?

      No habit-forming tendencies were reported.

    • Usage in pregnancy?

      This medicine is not recommended for use in pregnant women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

    • Usage while breast-feeding?

      This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

    When not to use?

    • Allergy

      This medicine is not recommended for use in patients with a known allergy to Pamidria Injection 30 mg 1 Vial or any other components present along with it.

    Warnings

    Warnings for special population
    • Pregnancy

      This medicine is not recommended for use in pregnant women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

    • Breast-feeding

      This medicine is not recommended for use in breastfeeding women unless absolutely necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

    General Warnings
    • Driving or Operating machinery

      This medicine may cause dizziness or drowsiness in some patients. It is advised that you do not perform any activities that require high mental alertness like driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

    • Osteonecrosis of the Jaw

      This medicine may rarely cause osteonecrosis of the jaw in some patients. This risk is especially higher in patients undergoing invasive dental procedures. Report any unusual symptoms to the doctor immediately. Appropriate dose adjustments or replacement with a suitable alternative may be necessary in some cases based on the clinical condition

    • Severe bone, joint, and/or muscle pain

      This medicine may cause severe bone, joint, and/or muscle pain. Report any such symptoms to the doctor on priority. Your doctor may advise you to discontinue therapy based on your clinical condition.

    • Thigh and hip bone fracture

      Use of this medicine may increase the risk of a thigh and hip bone fracture. Care should be taken to avoid any falls or other trauma to reduce this risk.

    • Use in children

      This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.

    • Electrolyte abnormalities

      This medicine may cause an imbalance of electrolyte levels in the body and therefore should be used with extreme caution in patients with or who are at risk of developing electrolyte abnormalities due to the increased risk of worsening of the patient's condition. Close monitoring of electrolyte levels is necessary while receiving this medicine. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition.

    • Bone marrow suppression

      This medicine should be used with extreme caution in patients with bone marrow suppression due to the increased risk of worsening of the patient's condition. Close monitoring of the clinical condition, dose adjustments, or replacement with a suitable alternative may be required in some cases based on the clinical condition.

    Dosage

    • Missed Dose

      Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of a missed dose is very low.

    • Overdose

      Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.

    Interactions

    Interaction with Medicines
    • Amikacin moderate
    • Deferasirox severe
    • Sirolimus severe
    • Methotrexate moderate
    • Torsemide moderate
    • Capreomycin moderate
    • Etecalcetide severe
    Disease interactions
    • moderate

      This medicine should be used with caution in patients with renal impairment due to the increased risk of severe adverse effects. Close monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

    General Instructions

    This medicine is usually administered by a qualified healthcare professional. Follow all the instructions given by your doctor and do not miss an appointment to receive this medicine. Consult the doctor if you experience any undesirable effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.

    Other details

    • Usage does not depend on food timings
    • To be taken as instructed by doctor
    • Causes sleepiness

    References

    Additional Information>

    How to use Pamidria Injection 30 mg 1 Vial

    IV: Drug must be properly diluted before administration and slowly infused IV (over at least 2 hours).
    Reconstitution: Powder for injection: Reconstitute by adding 10 mL of SWFI to each vial of lyophilized pamidronate disodium powder, the resulting solution will be 30 mg/mL or 90 mg/mL. Pamidronate may be further diluted in 250-1000 mL of 0.45% or 0.9% NaCl or D5W.
    Stability: Powder for injection: Store below 30°C. The reconstituted solution made by adding 10 mL of SWFI to each vial of lyophilized powder (30 mg/10 mL or 90 mg/10 mL) will be stable for 24 hours stored under refrigeration at 2°C-8°C. Solution for injection: Store at 20°C-25°C.

    what are the adverse effects of Pamidria Injection 30 mg 1 Vial?

    Mild transient pyrexia. Transient lymphocytopenia. Asymptomatic hypocalcaemia. Hypomagnesaemia, infusion site reactions, transient bone pain, arthralgia, myalgia, headache. GI upset, lymphocytopenia. Rarely, leucopenia, anaemia, other biochemical disturbances.

    What happens if I miss a dose of Pamidria Injection 30 mg 1 Vial?

    Adults: INJECTION: By slow IV infusion; max rate 60 mg/hr.
    Tumour induced hypercalcaemia: Total dosage to be determined by patients initial plasma calcium levels. Infuse slowly; max rate 30 mg in 2 hr. Max dose 90 mg per treatment for both initial and repeat courses. See literature.
    Osteolytic lesions, bone pain: 90 mg every 4 wk. In breast cancer this dose may be given every 3 wk to coincide with chemotherapy.
    Paget’s disease: 30 mg once wkly for 6 consecutive wk; total dose 180 mg. Alternatively, 30 mg in wk 1, then 60 mg in wk 2, wk 4 and wk 6; total dose 210 mg. Increase if necessary to a max total dose 360 mg. Regimen can be repeated every 6 mth until remission and if relapse occurs.
    Children: Not recommended.
    CAPSULE: Adults: 200 mg daily. Children: Not recommended.

    One of the following licensed pharmacy from the nearest location will deliver Pamidria Injection 30 mg 1 Vial. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.

    Questions and Answers

    There are no questions yet. Be the first to ask a question about this product.

    Only registered users are eligible to enter questions

    Medicalstore.com.pk © All rights reserved

    Made with ❤ by Dairah

    Shopping Cart